[424B5] Vivos Therapeutics, Inc. Prospectus Supplement (Debt Securities)
Vivos Therapeutics filed a prospectus supplement updating its at-the-market program under its Form S-3. The company may offer and sell common stock with an aggregate offering price of up to $3,583,686 from time to time through H.C. Wainwright & Co., as sales agent, pursuant to General Instruction I.B.6 of Form S-3.
This update reflects current I.B.6 capacity and excludes approximately $4,605,773 of shares previously sold under the prior prospectus. The public float was approximately $35,068,378, calculated from 7,477,266 non‑affiliate shares at $4.69 per share as of August 26, 2025. Over the past 12 months, the company sold securities with an aggregate market value of approximately $8,105,774 under I.B.6. VVOS last traded at $2.97 on October 23, 2025.
Vivos Therapeutics ha depositato un supplemento al prospetto aggiornando il suo programma at-the-market ai sensi del Form S-3. La società può offrire e vendere azioni ordinarie per un prezzo di offerta aggregato fino a $3,583,686 da volta a volta attraverso H.C. Wainwright & Co., come agente di vendita, ai sensi della Istruzione Generale I.B.6 del Form S-3.
Questo aggiornamento riflette l'attuale capacità I.B.6 e esclude circa $4,605,773 di azioni precedentemente vendute secondo il prospetto precedente. Il flottante pubblico era di circa $35,068,378, calcolato da 7,477,266 azioni non affiliate a $4,69 per azione al 26 agosto 2025. Nel corso degli ultimi 12 mesi, la società ha venduto valori mobiliari per un valore di mercato aggregato di circa $8,105,774 ai sensi di I.B.6. VVOS è stato scambiato per l'ultima volta a $2,97 il 23 ottobre 2025.
Vivos Therapeutics presentó un suplemento al prospecto que actualiza su programa en el mercado bajo su Formulario S-3. La empresa puede ofrecer y vender acciones comunes por un precio agregado de hasta $3,583,686 de tiempo en tiempo a través de H.C. Wainwright & Co., como agente de ventas, conforme a la Instrucción General I.B.6 del Form S-3.
Esta actualización refleja la capacidad actual de I.B.6 y excluye aproximadamente $4,605,773 de acciones vendidas previamente bajo el prospecto anterior. El flotante público era de aproximadamente $35,068,378, calculado a partir de 7,477,266 acciones no afiliadas a $4,69 por acción al 26 de agosto de 2025. En los últimos 12 meses, la compañía vendió valores con un valor de mercado agregado de aproximadamente $8,105,774 bajo I.B.6. VVOS cotizó por última vez a $2,97 el 23 de octubre de 2025.
Vivos Therapeutics는 Form S-3에 따라 시장에서의 공모 주식 프로그램을 업데이트하는 프로스펙터스 보충서를 제출했습니다. 회사는 주당가치 합계가 최대 $3,583,686까지의 보통주를 시간에 따라 H.C. Wainwright & Co.를 매매대행자로 하여 매도할 수 있습니다. 이는 Form S-3의 일반 지침 I.B.6에 따른 것입니다.
이 업데이트는 현재 I.B.6 용량을 반영하고, 이전 프로스펙터스에 따라 이전에 팔린 주식 약 $4,605,773를 제외합니다. 공모유통 주식(public float)은 대략 $35,068,378였고, 8월 26, 2025 기준으로 주당 4.69달러로 비계열 주식 7,477,266주에서 산출되었습니다. 지난 12개월 동안, 회사는 I.B.6에 따라 합계 약 $8,105,774의 시가로 유가증권을 팔았습니다. VVOS의 마지막 거래가는 2025년 10월 23일에 $2.97였습니다.
Vivos Therapeutics a déposé un supplément de prospectus actualisant son programme sur le marché auprès de son Form S-3. La société peut offrir et vendre des actions ordinaires pour une valeur d'offre globale allant jusqu'à 3 583 686 dollars de temps à autre par l'intermédiaire de H.C. Wainwright & Co., en tant qu'agent de vente, conformément à l'Instruction générale I.B.6 du Form S-3.
Cette mise à jour reflète la capacité actuelle de I.B.6 et exclut environ 4 605 773 dollars d'actions précédemment vendues dans le cadre du prospectus antérieur. Le flottant public était d'environ 35 068 378 dollars, calculé à partir de 7 477 266 actions non affiliées à 4,69 dollars par action au 26 août 2025. Au cours des 12 derniers mois, la société a vendu des valeurs mobilières d'une valeur marchande aggregée d'environ 8 105 774 dollars sous I.B.6. VVOS a été négocié pour la dernière fois à 2,97 dollars le 23 octobre 2025.
Vivos Therapeutics hat einen Prospekt-Supplement eingereicht, der sein At-the-Market-Programm im Rahmen des Form S-3 aktualisiert. Das Unternehmen kann gelegentlich Stammaktien mit einem gesamten Angebotswert von bis zu 3.583.686 USD über H.C. Wainwright & Co. als Verkaufsagenten gemäß der General Instruction I.B.6 des Form S-3 anbieten und verkaufen.
Diese Aktualisierung spiegelt die derzeitige I.B.6-Kapazität wider und schließt ca. 4.605.773 USD an Aktien aus, die zuvor unter dem früheren Prospekt verkauft wurden. Der öffentliche Streubesitz betrug ca. 35.068.378 USD, berechnet aus 7.477.266 nicht verbundenen Aktien zu 4,69 USD pro Aktie zum 26. August 2025. In den letzten 12 Monaten hat das Unternehmen Wertpapiere im Gesamtmarktwert von ca. 8.105.774 USD unter I.B.6 verkauft. VVOS wurde zuletzt am 23. Oktober 2025 zu 2,97 USD gehandelt.
قدمت Vivos Therapeutics ملحقاً للاكتتاب يعيد تحديث برنامجها في السوق العادية بموجب نموذج S-3. قد تعرض الشركة وتبيع أسهم عادية بمبلغ إجمالي حتى $3,583,686 من حين لآخر من خلال H.C. Wainwright & Co.، كوكيل مبيعات، وفقاً للتعليمات العامة I.B.6 من النموذج S-3.
يعكس هذا التحديث القدرة الحالية لـ I.B.6 ويستبعد نحو $4,605,773 من الأسهم التي تم بيعها سابقاً بموجب النشرة السابقة. كان التدفق العائم العام نحو $35,068,378، محسوباً من 7,477,266 سهماً غير تابعين عند $4.69 للسهم حتى 26 أغسطس 2025. خلال 12 الشهر الماضي، باعت الشركة أوراق مالية بقيمة سوقية إجمالية نحو $8,105,774 بموجب I.B.6. وتم التداول على VVOS آخر مرة عند $2.97 في 23 أكتوبر 2025.
- None.
- None.
Vivos Therapeutics ha depositato un supplemento al prospetto aggiornando il suo programma at-the-market ai sensi del Form S-3. La società può offrire e vendere azioni ordinarie per un prezzo di offerta aggregato fino a $3,583,686 da volta a volta attraverso H.C. Wainwright & Co., come agente di vendita, ai sensi della Istruzione Generale I.B.6 del Form S-3.
Questo aggiornamento riflette l'attuale capacità I.B.6 e esclude circa $4,605,773 di azioni precedentemente vendute secondo il prospetto precedente. Il flottante pubblico era di circa $35,068,378, calcolato da 7,477,266 azioni non affiliate a $4,69 per azione al 26 agosto 2025. Nel corso degli ultimi 12 mesi, la società ha venduto valori mobiliari per un valore di mercato aggregato di circa $8,105,774 ai sensi di I.B.6. VVOS è stato scambiato per l'ultima volta a $2,97 il 23 ottobre 2025.
Vivos Therapeutics presentó un suplemento al prospecto que actualiza su programa en el mercado bajo su Formulario S-3. La empresa puede ofrecer y vender acciones comunes por un precio agregado de hasta $3,583,686 de tiempo en tiempo a través de H.C. Wainwright & Co., como agente de ventas, conforme a la Instrucción General I.B.6 del Form S-3.
Esta actualización refleja la capacidad actual de I.B.6 y excluye aproximadamente $4,605,773 de acciones vendidas previamente bajo el prospecto anterior. El flotante público era de aproximadamente $35,068,378, calculado a partir de 7,477,266 acciones no afiliadas a $4,69 por acción al 26 de agosto de 2025. En los últimos 12 meses, la compañía vendió valores con un valor de mercado agregado de aproximadamente $8,105,774 bajo I.B.6. VVOS cotizó por última vez a $2,97 el 23 de octubre de 2025.
Vivos Therapeutics는 Form S-3에 따라 시장에서의 공모 주식 프로그램을 업데이트하는 프로스펙터스 보충서를 제출했습니다. 회사는 주당가치 합계가 최대 $3,583,686까지의 보통주를 시간에 따라 H.C. Wainwright & Co.를 매매대행자로 하여 매도할 수 있습니다. 이는 Form S-3의 일반 지침 I.B.6에 따른 것입니다.
이 업데이트는 현재 I.B.6 용량을 반영하고, 이전 프로스펙터스에 따라 이전에 팔린 주식 약 $4,605,773를 제외합니다. 공모유통 주식(public float)은 대략 $35,068,378였고, 8월 26, 2025 기준으로 주당 4.69달러로 비계열 주식 7,477,266주에서 산출되었습니다. 지난 12개월 동안, 회사는 I.B.6에 따라 합계 약 $8,105,774의 시가로 유가증권을 팔았습니다. VVOS의 마지막 거래가는 2025년 10월 23일에 $2.97였습니다.
Vivos Therapeutics a déposé un supplément de prospectus actualisant son programme sur le marché auprès de son Form S-3. La société peut offrir et vendre des actions ordinaires pour une valeur d'offre globale allant jusqu'à 3 583 686 dollars de temps à autre par l'intermédiaire de H.C. Wainwright & Co., en tant qu'agent de vente, conformément à l'Instruction générale I.B.6 du Form S-3.
Cette mise à jour reflète la capacité actuelle de I.B.6 et exclut environ 4 605 773 dollars d'actions précédemment vendues dans le cadre du prospectus antérieur. Le flottant public était d'environ 35 068 378 dollars, calculé à partir de 7 477 266 actions non affiliées à 4,69 dollars par action au 26 août 2025. Au cours des 12 derniers mois, la société a vendu des valeurs mobilières d'une valeur marchande aggregée d'environ 8 105 774 dollars sous I.B.6. VVOS a été négocié pour la dernière fois à 2,97 dollars le 23 octobre 2025.
Vivos Therapeutics hat einen Prospekt-Supplement eingereicht, der sein At-the-Market-Programm im Rahmen des Form S-3 aktualisiert. Das Unternehmen kann gelegentlich Stammaktien mit einem gesamten Angebotswert von bis zu 3.583.686 USD über H.C. Wainwright & Co. als Verkaufsagenten gemäß der General Instruction I.B.6 des Form S-3 anbieten und verkaufen.
Diese Aktualisierung spiegelt die derzeitige I.B.6-Kapazität wider und schließt ca. 4.605.773 USD an Aktien aus, die zuvor unter dem früheren Prospekt verkauft wurden. Der öffentliche Streubesitz betrug ca. 35.068.378 USD, berechnet aus 7.477.266 nicht verbundenen Aktien zu 4,69 USD pro Aktie zum 26. August 2025. In den letzten 12 Monaten hat das Unternehmen Wertpapiere im Gesamtmarktwert von ca. 8.105.774 USD unter I.B.6 verkauft. VVOS wurde zuletzt am 23. Oktober 2025 zu 2,97 USD gehandelt.
قدمت Vivos Therapeutics ملحقاً للاكتتاب يعيد تحديث برنامجها في السوق العادية بموجب نموذج S-3. قد تعرض الشركة وتبيع أسهم عادية بمبلغ إجمالي حتى $3,583,686 من حين لآخر من خلال H.C. Wainwright & Co.، كوكيل مبيعات، وفقاً للتعليمات العامة I.B.6 من النموذج S-3.
يعكس هذا التحديث القدرة الحالية لـ I.B.6 ويستبعد نحو $4,605,773 من الأسهم التي تم بيعها سابقاً بموجب النشرة السابقة. كان التدفق العائم العام نحو $35,068,378، محسوباً من 7,477,266 سهماً غير تابعين عند $4.69 للسهم حتى 26 أغسطس 2025. خلال 12 الشهر الماضي، باعت الشركة أوراق مالية بقيمة سوقية إجمالية نحو $8,105,774 بموجب I.B.6. وتم التداول على VVOS آخر مرة عند $2.97 في 23 أكتوبر 2025.
Vivos Therapeutics 已提交一份招股说明书补充文件，更新其基于 Form S-3 的在市场发行计划。公司可以通过销售代理人 H.C. Wainwright & Co. 不时发行和出售普通股，综合发行价格最高可达 $3,583,686，依据 Form S-3 的通用指令 I.B.6。
本次更新反映了当前的 I.B.6 容量，并排除了大约 $4,605,773 的在前一份招股说明书下已出售的股份。公开流通股本约为 $35,068,378，以 2025 年 8 月 26 日时每股 4.69 美元、非关联股数 7,477,266 股计算。过去 12 个月内，公司在 I.B.6 下以合计市值约 $8,105,774 出售证券。VVOS 于 2025 年 10 月 23 日最后交易，价格为 $2.97。
PROSPECTUS SUPPLEMENT
(To Prospectus Supplement Dated September 12, 2025)
Filed
Pursuant to Rule 424(b)(5)
Registration No. 333-284834
Up to $3,583,686
Common Stock
This prospectus supplement amends and supplements the information in the prospectus, dated September 10, 2025, filed as a part of our registration statement on Form S-3 (File No. 333-284834), or the Registration Statement, as supplemented by our prospectus supplement, dated September 12, 2025 (collectively the “Prior Prospectus”), relating to the offering, issuance and sale by us of our common stock from time to time that may be issued and sold under the at the market offering agreement, dated February 14, 2025 (the “Sales Agreement”), by and between us and H.C. Wainwright & Co., LLC (“Wainwright”), as sales agent. This prospectus supplement should be read in conjunction with the Prior Prospectus, and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the Prior Prospectuses. This prospectus supplement is not complete without, and may only be delivered or utilized in connection with, the Prior Prospectus, and any future amendments or supplements thereto.
We are filing this prospectus supplement to amend the Prior Prospectus to update the maximum amount of shares we are eligible to sell under our Registration Statement pursuant to General Instruction I.B.6 of Form S-3. As a result of these limitations and the current public float of our common stock, and in accordance with the terms of the Sales Agreement, we may offer and sell shares of our common stock having an aggregate offering price of up to $3,583,686 from time to time through Wainwright, which does not include the shares of common stock having an aggregate sales price of approximately $4,605,773 that were sold pursuant to the Prior Prospectus to date. In the event that we may sell additional amounts under the Sales Agreement in accordance with General Instruction I.B.6, we will file another prospectus supplement prior to making such additional sales.
As of the date of this prospectus supplement, the aggregate market value of our outstanding common stock held by non-affiliates, or the public float, was approximately $35,068,378, which was calculated based on 7,477,266 shares of our outstanding common stock held by non-affiliates at a price of $4.69 per share, the closing price of our common stock on the Nasdaq Capital Market on August 26, 2025. During the 12 calendar months prior to, and including, the date of this prospectus supplement, we sold securities with an aggregate market value of approximately $8,105,774 pursuant to General Instruction I.B.6 of Form S-3.
Our common stock is listed on the Nasdaq Capital Market under the symbol “VVOS.” On October 23, 2025, the last reported sale price of our common stock on the Nasdaq Capital Market was $2.97 per share.
Investing in our common stock is speculative involves a high degree of risk. See “Risk Factors,” beginning on page S-10 of the Prior Prospectus, as well as the risks discussed under similar headings in the documents incorporated by reference in this prospectus supplement and the Prior Prospectus (as they may be amended, updated or modified periodically in our reports filed with the Securities and Exchange Commission), for a discussion of the factors you should carefully consider before deciding to purchase our securities.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the accompanying Prior Prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
H.C. Wainwright & Co.
The date of this prospectus supplement is October 24, 2025
FAQ
What is VVOS offering in this prospectus supplement?
How much can VVOS sell under the updated ATM?
How much has VVOS already sold under the prior prospectus?
What is VVOS’s current public float used for I.B.6 limits?
How much did VVOS sell under I.B.6 in the past 12 months?
What is VVOS’s stock symbol and recent price?
Who receives proceeds from these sales?
